Floatz logo

HUMAN NATURAL KILLER CELL LINE NK-92 (CD16.158V, ER IL2) CELLS

Triple Negative Breast Cancer

ImmunityBio, Inc.Cell therapyPhase 2Dormant
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
22/ 100
Competitive Position
65/ 100

Competitive context

448 Active assets in the Triple Negative Breast Cancer cohort.

Asset / SponsorPhaseRating
Capivasertib
AstraZeneca
Phase 3BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 4BB
Carboplatin
M.D. Anderson Cancer Center
Phase 4BB
Veliparib
National Cancer Institute (NCI)
Phase 3BB
Atezolizumab
European Institute of Oncology
Phase 3BB

View all 50 →

Same molecule, other indications

HUMAN NATURAL KILLER CELL LINE NK-92 (CD16.158V, ER IL2) CELLS is also rated in:

non-small cell lung carcinomaDormant
C
Indicative ·
37 / 100
View asset →
malignant pancreatic neoplasmDormant
C
Indicative ·
33 / 100
View asset →
non-Hodgkin lymphomaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →